KRAS and familial pancreatic carcinoma: Mukhopadhyay et al. showed that the NRF2 contributed to chemo-resistance in KRAS mutated pancreatic cancer cells and targeting these cell lines with glutaminase inhibitors sensitized the KRAS mutant cells to chemotherapy [69].